-
-
Pharmtech Focus (December 9, 2022) Molecular Devices Acquires Cellesce, Expanding Industrywide Accessibility to Organoids
Molecular Devices, a leading provider of high-performance life science solutions, has announced the acquisition of Cellesce which specializes in contract development and manufacturing of large-scale patient-derived organoids (PDOs) for diverse applications, including drug screening.
The Scientist (December 8, 2022) Cell Culture Conquests: Finding and Defeating the Invisible Enemy
Cutting-edge reagents, kits, and techniques provide a robust solution to cell culture mycoplasma contamination.
Genetic Engineering and Biotechnology News (December 8, 2022) Heart Attacks Mimicked on a Chip
Scientists at the University of Southern California Alfred E. Mann Department of Biomedical Engineering say they have developed a “heart attack on a chip,” a device that could one day serve as a method for developing new heart drugs and even personalized medicines.
Reuters (December 6, 2022) Exclusive: Musk’s Neuralink faces federal probe, employee backlash over animal tests
Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations.
Business Insider (December 5, 2022) The pandemic was a crisis that fueled interest in novel drug discovery methods like AI. These 14 startups are predicted by investors to be future winners.
Drug discovery, a process which aims to develop new medications and therapeutics, has long been a costly and time-consuming process. The return on impact, however, is projected to be high. Business Insider asked investors with biotech expertise for the startups that are set to take off. This article lists what they said. (PDF attached)
Genetic Engineering and Biotechnology News (December 2, 2022) 3D Organoid Model Developed for Gastroesophageal Junction Cancer
Scientists at Johns Hopkins Medicine and colleagues say they have created a lab-grown organoid model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction.
-
- You must be logged in to reply to this topic.